Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$38.05
▼ $1.08 (-2.8%)
Market data updated: 10/02 09:36 AM
Fundamentals updated: 10/02/2026
News analyzed: 10/02/2026
Market Cap
$1.78B
Day Range
$37.81 - $39.50
52-Week Range
$17.55 - $51.10
Beta
—
Next Earnings
09.11.2026
Support
$32.47
Resistance
$51.10
SEPN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+100.3% (1Y)
Strengths: 9/26 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $63.23 vs. price $38.05 (+66.2%)
Fair Value
Biggest negative driver
Operating margin
Operating margin: -148.6% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
54
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
42
Value
62
Momentum
41
Risk
40
Sentiment
100
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Septerna, Inc. has centered on its financial performance and analyst optimism. The company reported a narrower Q2 loss while exceeding revenue estimates, signaling improved business progress. Analysts from Guggenheim, HC Wainwright, and Wells Fargo raised their price targets, maintaining positive ratings, while Septerna also announced the appointment of Rajiv Patni as Chief Medical Officer and upcoming investor conference participation.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Septerna, Inc.. News trend score: 100. Reason: 11 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
26
🎯 Conviction (vs. Emotion)
83
Psychology
72
Fundamentals
30
Technical
41
Valuation
62
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+12%
Market Narrative
49
Fundamental Reality
83
Narrative Gap
-34
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for SEPN suggests a detached euphoria, where extreme positive sentiment and valuation disconnect overshadow weak momentum and negative price-earnings alignment. Investors appear to prioritize narrative-driven optimism over fundamental or technical signals, creating a narrative-reality gap. The lack of panic or herding implies confidence in the story despite contradictory data. The key question is whether this disconnect will persist or if a catalyst will force a reassessment of the stock’s valuation.
Updated: 10/01/2026, 08:47 AM
What could change this?
👥 What the crowd believes
"Wells Fargo raises price target from $48 to $50"
"HC Wainwright & Co. maintains Buy on Septerna"
"Sales $26.746M beat $17.875M estimate"
"Appoints Industry Veteran Rajiv Patni as CMO"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Thorstein Veblen — 12/100
🗣️ Why do they disagree?
The stark divide in verdicts for SEPN reflects deep methodological contrasts: Bagehot’s near-perfect score highlights its liquidity resilience, aligning with his focus on financial stability during crises, while Lynch and Nelson’s growth and cyclical optimism suggest undervalued momentum or oversold conditions. Meanwhile, Fisher and Graham’s mid-range scores reveal caution—Fisher’s bar for exceptional quality isn’t met, and Graham’s mixed verdict hints at inconsistent fundamentals. On the other end, Veblen’s low score and Marks’ late-cycle warning flag speculative or overvalued traits, contrasting sharply with Bagehot’s defensive stance. The middle ground (e.g., Housel, Smith) acknowledges holdability but lacks the conviction of the top-tier methodologies, illustrating how SEPN’s profile appeals to some principles (like liquidity or cyclical timing) while failing others (like trend alignment or efficiency).
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 81
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 75
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 67
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 60
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 60
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 51
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 48
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 40
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 39
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 32
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 12
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 291 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 5 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-148.6%
Net Margin
-106.4%
EBITDA Margin
-145.1%
ROE
-12.8%
ROA
-8.2%
ROIC
—
EPS
-$1.10
Cash
$120.72M
Total Debt
—
Current Ratio
4.73
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$38.05
Estimated Fair Value (DCF)
$63.23
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+66.2%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $137.09M | $125.77M |
| 2 | 19.4% | $163.65M | $137.74M |
| 3 | 13.8% | $186.15M | $143.74M |
| 4 | 8.1% | $201.28M | $142.59M |
| 5 | 2.5% | $206.31M | $134.09M |
Base FCF (last actual year)
$109.67M
Terminal Value
$3.25B
Present Value of Terminal Value
$2.11B
Enterprise Value
$2.80B
Net Debt
$0
Equity Value
$2.80B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$8.63
Tangible Book Value per Share (Tangible NAV)
$8.63
Sentiment based on basic keywords (not AI) — 11 positive, 8 neutral, 1 negative out of the last 20 articles.
GlobeNewswire · 1.9.2026
GlobeNewswire · 25.8.2026
Benzinga · 12.8.2026
Benzinga · 12.8.2026
Benzinga · 11.8.2026
Zacks · 10.8.2026
MT Newswires · 10.8.2026
GlobeNewswire · 10.8.2026
Benzinga · 10.8.2026
Zacks · 6.8.2026
Zacks · 5.8.2026
Motley Fool · 5.7.2026
Insider Monkey · 2.7.2026
Motley Fool · 30.6.2026
MT Newswires · 11.6.2026
PR Newswire · 8.6.2026
Simply Wall St. · 17.5.2026
Simply Wall St. · 15.5.2026
Zacks · 11.5.2026
GlobeNewswire · 11.5.2026
Septerna, Inc. (SEPN) currently has a StockIQ AI score of 54/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
SEPN currently scores 54/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, SEPN's estimated fair value is $63.23, which is 66.2% above the current price of $38.05. This is one valuation model among several signals in the fair-value category, not a price target.
SEPN's technical score is 41/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $63.23 vs. price $38.05 (+66.2%); Revenue growth (last year): 4174.5%; Earnings per share (EPS) growth: 84.8%.
Based on the real signals StockIQ computed: Operating margin: -148.6% (negative); Net margin: -106.4% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for SEPN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 12 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Patni Rajiv | Grant/Award from Employer | 8.9.2026 | 275,000 | +275,000 | — |
| Long Daniel D. | Exercise of Derivative Securities | 1.9.2026 | 99,745 | +3,333 | $2.76 |
| Long Daniel D. | Open Market Sale | 1.9.2026 | 96,412 | -3,333 | $37.83 |
| Long Daniel D. | Exercise of Derivative Securities | 1.9.2026 | 9,085 | -3,333 | — |
| Third Rock Ventures V, L.P. | Open Market Sale | 12.8.2026 | 147,059 | +147,059 | $50.27 |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Sale | 12.8.2026 | 746,500 | -746,500 | $42.50 |
| Third Rock Ventures V, L.P. | Open Market Sale | 12.8.2026 | 141 | +141 | $51.08 |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Sale | 12.8.2026 | 746,500 | -746,500 | $42.50 |
| Third Rock Ventures V, L.P. | Open Market Sale | 12.8.2026 | 6,068,532 | +147,059 | $50.27 |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Sale | 12.8.2026 | 4,777,415 | -746,500 | $42.50 |
| Third Rock Ventures V, L.P. | Open Market Sale | 12.8.2026 | 6,068,391 | +141 | $51.08 |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Sale | 12.8.2026 | 725,443 | -746,500 | $42.50 |
| Bhatt Elizabeth | Exercise of Derivative Securities | 11.8.2026 | 6,319 | -6,319 | — |
| Bhatt Elizabeth | Exercise of Derivative Securities | 11.8.2026 | 6,319 | +6,319 | $2.76 |
| Bhatt Elizabeth | Open Market Sale | 11.8.2026 | 25,000 | -25,000 | $44.00 |
| Bhatt Elizabeth | Exercise of Derivative Securities | 11.8.2026 | 18,681 | +18,681 | $6.81 |
| Bhatt Elizabeth | Exercise of Derivative Securities | 11.8.2026 | 18,681 | -18,681 | — |
| Bhatt Elizabeth | Exercise of Derivative Securities | 11.8.2026 | 192,890 | +18,681 | $6.81 |
| Bhatt Elizabeth | Exercise of Derivative Securities | 11.8.2026 | 199,209 | +6,319 | $2.76 |
| Bhatt Elizabeth | Exercise of Derivative Securities | 11.8.2026 | 82,332 | -6,319 | — |
| Bhatt Elizabeth | Open Market Sale | 11.8.2026 | 174,209 | -25,000 | $44.00 |
| Bhatt Elizabeth | Exercise of Derivative Securities | 11.8.2026 | 62,230 | -18,681 | — |
| Long Daniel D. | Exercise of Derivative Securities | 3.8.2026 | 1,518 | -1,518 | — |
| Long Daniel D. | Exercise of Derivative Securities | 3.8.2026 | 1,816 | -1,816 | — |
| Long Daniel D. | Open Market Sale | 3.8.2026 | 1,000 | -1,000 | $33.98 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,894,002 shares short as of 2026-09-15 · vs. 2,718,332 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
61.6% of trading volume this week was short selling, vs. 59.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology